Sun BioPharma Inc. is a clinical stage bio pharmaceutical company developing disruptive therapeutics for significant unmet medical needs. The Company s initial programs are aimed at diseases of the pancreas, including pancreatic cancer and pancreatitis. The Company has completed enrollment in its first in human Phase a clinical safety trial of SBP , in the treatment of previously treated pancreatic cancer patients. The trial established a safe and well tolerated dose. The Company anticipates initiation of patient enrollment in its next clinical trial in the first quarter of which will be a Phase a/ b study of the safety and efficacy of SBP administered in combination with gemcitabine and nab paclitaxel. Sun BioPharma has scientific collaborations with pancreatic disease experts the Mayo Clinic Scottsdale and Cedars Sinai Medical Center in the US, the University of Miami, the Austin Health Cancer Trials Centre and the Ashford Cancer Centre in Australia. SBP is a novel small molecule synthetic polyamine compound designed to exert therapeutic effects in a mechanism of action specific to the pancreas. SBP has been shown to be highly effective in several human pancreatic cancer models, demonstrating superior activity to existing chemotherapy agents. Combination potential has also been shown for pancreatic cancer. SBP is expected to hold an edge over current pancreatic cancer therapies, as it specifically targets the exocrine pancreas.
Quote | Sun BioPharma Inc (OTCMKTS:SNBP)
Last: | $3.19 |
---|---|
Change Percent: | -66.42% |
Open: | $3.3 |
Close: | $3.19 |
High: | $3.6 |
Low: | $3.16 |
Volume: | 540,134 |
Last Trade Date Time: | 08/28/2020 04:54:40 pm |
News | Sun BioPharma Inc (OTCMKTS:SNBP)
MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the s...
MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective ...
Message Board Posts | Sun BioPharma Inc (OTCMKTS:SNBP)
Subject | By | Source | When |
---|---|---|---|
SNBP $3.05,monsta run ahead | ALERTS100%to10000%GAIN | investorshub | 10/16/2020 5:04:37 PM |
News, Short Squeeze, Breakout and More Instantly...
MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the s...
MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective ...
MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quart...